Intervention review — page 2
A review of the effects of an intervention on pre-specified outcomes, with a quantitative synthesis where the contributing studies are sufficiently similar.
Reviews
-
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High04 Oct 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High16 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High28 Jul 2026 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate17 May 2025 -
In the population defined for obesity and overweight in adults, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the contributing trials?
Moderate13 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate17 Oct 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Lixisenatide maintained across the full duration of the contributing trials?
High03 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Lixisenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High01 Nov 2024 -
In the population defined for type 2 diabetes mellitus, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate21 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate15 Feb 2026 -
In the population defined for obesity and overweight in adults, is the effect of Survodutide maintained across the full duration of the contributing trials?
Moderate10 May 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Survodutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate05 Sep 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, is the effect of Thymosin alpha-1 maintained across the full duration of the contributing trials?
Moderate26 Aug 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate09 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, is the effect of Exenatide maintained across the full duration of the contributing trials?
High25 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High29 Jan 2026 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025
page 2 of 4